Masaki Setoguchi

Discovery of <i>trans</i>-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4<i>S</i>)-methoxy-(2<i>S</i>)-pyrrolidinylmethoxy]cyclohexanecarboxylic Acid: An Orally Active, Selective Very Late Antigen-4 Antagonist

Fumihito Muro, Shin Iimura, Yuuichi Sugimoto et al. · Journal of Medicinal Chemistry · 2009 · 25 citations · Full text

Pharmaceutical Science, Immunology, Orally Active +19

Chiral synthesis of the CD ring unit of paclitaxel from d-glucal

Takayuki Momose, Masaki Setoguchi, Toshiki Fujita et al. · Chemical Communications · 2000 · 24 citations

A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid

Masaki Setoguchi, Shin Iimura, Yuuichi Sugimoto et al. · Bioorganic & Medicinal Chemistry · 2012 · 23 citations · Full text

Medicinal Chemistry, Pharmaceutical Science, Medicine +9

Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma

Dimpy Koul, Shuzhen Wang, Shaofang Wu et al. · Oncotarget · 2017 · 20 citations · Full text

A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid

Fumihito Muro, Shin Iimura, Yoshiyuki Yoneda et al. · Bioorganic & Medicinal Chemistry · 2008 · 18 citations · Full text

Medicinal Chemistry, Medicine, Trans-4-substituted Cyclohexanecarboxylic Acid +6